<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00772863</url>
  </required_header>
  <id_info>
    <org_study_id>XRP6976I_6012</org_study_id>
    <nct_id>NCT00772863</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer</brief_title>
  <acronym>Tax-Over</acronym>
  <official_title>The Evaluation of Efficacy and Safety of Subsequent Cisplatin and Docetaxel Regimen In The First Line Treatment of Advanced Epithelial Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and the safety of the treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy by response rate according to RECIST criteria and safety</measure>
    <time_frame>After the 2nd cycle, 4th cycle and 8th cycle and at the follow up period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression or relapse</measure>
    <time_frame>Until progression througout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival time</measure>
    <time_frame>Througout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life based on the questionnaire EORTC QLQ-C30 filled by the patients</measure>
    <time_frame>Prior to entry, after completion of treatment and at the first follow-up visit</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">37</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel and cisplatin</intervention_name>
    <description>4 cycles Cisplatin 100 mg/m2 at every 3 weeks, after Cisplatin 4 cycles of docetaxel 100mg/m2 at every 3 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically/cytologically confirmed, optimally debulked stage III-IV epithelial&#xD;
             ovarian cancer excluding clear cell histology.&#xD;
&#xD;
          -  ECOG Performance Status is 0-2&#xD;
&#xD;
          -  No prior chemotherapy for this malignancy,&#xD;
&#xD;
          -  Acceptable hematological profile (as defined by a leukocyte count ≥ 3000/mm3, a&#xD;
             platelet count ≥ 100.000mm3 and Hb ≥ 9g/100mL), and adequate renal function (as&#xD;
             defined by serum creatinine ≤ 1.5mg/dl or creatinine clearance by formulation ≥ 60&#xD;
             mL/min), and hepatic function (as defined by bilirubin ≤ 1.5 x maximum normal value&#xD;
             even with hepatic metastasis; transaminases (ALT, AST) ≤ 1.5 x maximum normal value;&#xD;
             alkaline phosphatase ≤ 2.5 x maximum normal value, except in case of a bone&#xD;
             metastasis)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant use of another anti-cancer therapy&#xD;
&#xD;
          -  Unstable medical condition that makes the patient unable to take part in a clinical&#xD;
             study (congestive heart failure, serious arrythmia, uncontrolled diabetes mellitus),&#xD;
             history of myocardial infarction within last 3 months, massive pleural, peritoneal or&#xD;
             pericardial effusion; or presence of serious uncontrolled infection.&#xD;
&#xD;
          -  Presence of other tumours different from basal cell carcinoma of the skin.&#xD;
&#xD;
          -  Pregnancy or breastfeeding. In women of childbearing potential and in men, an adequate&#xD;
             contraceptive method must be used&#xD;
&#xD;
          -  Social or psychological condition that render the patient inadequate for the follow-up&#xD;
             of the study&#xD;
&#xD;
          -  Contraindication for any of the study drugs (e.g. history of hypersensitivity to any&#xD;
             of the ingredients of the study drugs)&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edibe Taylan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi aventis administrative office</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>October 13, 2008</study_first_submitted>
  <study_first_submitted_qc>October 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2008</study_first_posted>
  <last_update_submitted>October 28, 2009</last_update_submitted>
  <last_update_submitted_qc>October 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>Sanofi aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

